BioLife Solutions, Inc., announced that Casdin Capital LLC has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second largest shareholder, who has been a primary source of investment capital for the Company since its inception.
BOTHELL, Wash., April 9, 2018 /PRNewswire/ -- BioLife Solutions, Inc., (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that Casdin Capital LLC, ("Casdin") a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company's second largest shareholder, who has been a primary source of investment capital for the Company since its inception.
Mike Rice, BioLife CEO commented, "We extend a warm welcome to Casdin Capital as a new long term institutional investor. Casdin's long term investment thesis recognizes the enormous medical and investment impact of cellular medicine, including the role of the ecosystem of embedded tools providers, and as such is well aligned with our mission to become the leading provider of biopreservation tools for cells, tissues and organs."
About Casdin Capital
Casdin Capital LLC ("Casdin"), a NYC-based Life Science investment firm founded in 2012, brings a deep understanding, expertise and long term perspective to financing the next generation of life science innovation. For more information please visit https://www.casdincapital.com.
About BioLife Solutions
BioLife Solutions is the leading developer, manufacturer and supplier of proprietary, clinical-grade biopreservation media for cells and tissues. Our HypoThermosol® hypothermic storage and CryoStor® cryopreservation freeze media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
